-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*For medical professionals' reference only, November 30, 2021, from 19:00-20:30, the China Hepatitis Cloud Forum will be broadcast live on the Jizhi Medical Platform.
We will be there for you~ Editor's note: The World Health Organization proposes to eliminate the virus by 2030 However, today, due to the large stock of patients with chronic viral hepatitis in China, there is still a big gap between us and this goal
.
"The revolution has not yet succeeded, comrades still need to work harder.
" The goal of hepatitis C elimination is: compared with 2015, the rate of new HCV infections will be reduced by 90%, related deaths will be reduced by 65%, the diagnosis rate will reach 90%, and the treatment rate will reach 80%[1]
.
However, as of 2019, the cumulative diagnosis rate of hepatitis C in China is only 30%, and the cumulative treatment rate is 9% [2]
.
The prevalence of anti-HDV among HBsAg carriers in my country is 2%-5%, and the burden of disease caused by HDV infection is heavy! [3] Last weekend, the 72nd Annual Meeting of the American Society for the Study of Liver Diseases (AASLD) ended successfully.
At this year-end event in the field of liver disease, the exploration of hepatitis C and hepatitis D has never stopped
.
Want to know what wisdom domestic and foreign experts and scholars have contributed? In order to achieve the goal of eliminating viral hepatitis, what other positive actions can we take? Please lock it on November 30 from 19:00-20:30, Professor Wei Lai from Tsinghua Chang Gung Memorial Hospital, Tsinghua University, will take us to reveal the answer! Welcome to the AASLD knowledge and skills "gas station" live two-dimensional code Professor Luo Xinhua-digging into the latest data from multiple angles, an all-round "HCV sniper war" with the approval and clinical trials of direct antiviral drugs (DAAs) Widely used, chronic hepatitis C has been virologically cured
.
Through clinical treatment, the sustained virological response (SVR) of patients can reach more than 90%
.
According to a recent study on the global status of HCV prevalence and cascade care published by the AASLD annual meeting[4], the prevalence of HCV has declined since 2015, but it is still necessary to increase efforts to expand screening and treatment to achieve The goal of eliminating HCV by 2030
.
China has also taken the discovery of potential HCV infections and increasing the treatment rate of patients as an important strategy to eliminate hepatitis C [5]
.
Chinese scholars also shared real-world research data on DAA applications at this year's AASLD
.
In a global, multi-center, large-scale real-world study of DAA in Asian populations[6], despite the existence of a large number of patients with liver cirrhosis, liver cancer, previous treatment failure, GT3 or type 6, the overall cure rate of patients is still As high as 96.
7%
.
Two other studies have revealed [7,8] that for the GT3 and 6 patients with less real-world evidence, the SOF/VEL±RBV regimen has a high sustained virological response rate and good safety
.
In addition, for special hepatitis C patients undergoing hemodialysis [9], the 12-week SOF/VEL regimen also achieved good safety and efficacy
.
These real-world data from the clinical frontline reflect the outstanding achievements made by Chinese scholars in hepatitis C clearance
.
As we all know, the hepatitis C micro-elimination strategy is to provide targeted services for specific hepatitis C patients in order to reduce the incidence and mortality of hepatitis C more quickly and effectively
.
At present, there are the latest reports on the mode of hepatitis C micro-elimination at home and abroad [10-12]
.
At this annual meeting, a study by the team of Professor Luo Xinhua from Guizhou Provincial People's Hospital received much attention.
The study conducted an online survey of hepatitis C prevention and treatment knowledge for medical workers in 17 hospitals in Guizhou Province [10]
.
The research results suggest that we need to continue to expand the education of primary health care workers to increase their awareness of hepatitis C; at the same time, accelerate the implementation of medical insurance and other comprehensive strategies to improve the accessibility of treatment options, so as to successfully achieve the 2030 WHO The goal of eradicating the hepatitis virus
.
Dr.
Michael Mertens-a breakthrough in treatment, HDV cannot be ignored! The transmission of HDV mainly depends on the transmission of HBV.
Studies have shown that HDV infection will accelerate the progression of hepatitis and increase the risk of liver adverse events [13], and patients with HBV combined with HDV infection have higher comorbidities and complications than HBV.
Single infection [14]
.
Therefore, we should increase the intensity of screening HDV improve the diagnosis and treatment of hepatitis
.
The current AASLD conference announced the Phase III clinical trial (MYR301) of Blevirtide [15].
The results showed that after 48 weeks of Blevirtide treatment, the level of HDV RNA and the number of HDAg+ cells in the liver decreased significantly
.
In addition, the decline of the virus in the liver is also related to the decline of inflammatory gene expression, indicating that liver inflammation has improved
.
What other issues do you care about? Come and vote and let us know! From 19:00-20:30 on November 30th, listen to the wonderful sharing and lead clinical ingenuity to see or leave! References[1]World Health Organization.
Global health sector strategy on viral hepatitis 2016-2021.
Geneva,Switzerland:World Health Organization.
Available via https:// en/Accessed 2020-07-28.
[2]https://cdafound.
org/dashboard/polaris/dashboard.
htmls[3]Miao Z,et al.
Estimating the Global Prevalence,Disease Progression,and Clinical Outcome of Hepatitis Delta Virus Infection.
J Infect Dis.
2020 Apr 27;221(10):1677-1687.
[4]Blach S,et al.
Global Status Update On the HCV Prevalence and Cascade of Care Entering 2020.
AASLD 2021.
Oral 100.
[ 5] Chen Yuxin, Wu Chao.
The management process of in-hospital screening for viral hepatitis C in China (for trial implementation).
Chinese Journal of Hepatology, 2020,28(10):820-823.
[6]Ji P,et al.
Real-World Effectiveness and Safety of Interferon-Free DAAS for 14,676 Hepatitis C(CHC)Patients with Genotypes 1,2,3,4 And 6: A Multinational Study.
AASLD 2021. .
If you are not a medical and health professional, please do not participate or spread it
.
-End-This article is only used to provide scientific information to medical professionals and does not represent the platform's position
.
We will be there for you~ Editor's note: The World Health Organization proposes to eliminate the virus by 2030 However, today, due to the large stock of patients with chronic viral hepatitis in China, there is still a big gap between us and this goal
.
"The revolution has not yet succeeded, comrades still need to work harder.
" The goal of hepatitis C elimination is: compared with 2015, the rate of new HCV infections will be reduced by 90%, related deaths will be reduced by 65%, the diagnosis rate will reach 90%, and the treatment rate will reach 80%[1]
.
However, as of 2019, the cumulative diagnosis rate of hepatitis C in China is only 30%, and the cumulative treatment rate is 9% [2]
.
The prevalence of anti-HDV among HBsAg carriers in my country is 2%-5%, and the burden of disease caused by HDV infection is heavy! [3] Last weekend, the 72nd Annual Meeting of the American Society for the Study of Liver Diseases (AASLD) ended successfully.
At this year-end event in the field of liver disease, the exploration of hepatitis C and hepatitis D has never stopped
.
Want to know what wisdom domestic and foreign experts and scholars have contributed? In order to achieve the goal of eliminating viral hepatitis, what other positive actions can we take? Please lock it on November 30 from 19:00-20:30, Professor Wei Lai from Tsinghua Chang Gung Memorial Hospital, Tsinghua University, will take us to reveal the answer! Welcome to the AASLD knowledge and skills "gas station" live two-dimensional code Professor Luo Xinhua-digging into the latest data from multiple angles, an all-round "HCV sniper war" with the approval and clinical trials of direct antiviral drugs (DAAs) Widely used, chronic hepatitis C has been virologically cured
.
Through clinical treatment, the sustained virological response (SVR) of patients can reach more than 90%
.
According to a recent study on the global status of HCV prevalence and cascade care published by the AASLD annual meeting[4], the prevalence of HCV has declined since 2015, but it is still necessary to increase efforts to expand screening and treatment to achieve The goal of eliminating HCV by 2030
.
China has also taken the discovery of potential HCV infections and increasing the treatment rate of patients as an important strategy to eliminate hepatitis C [5]
.
Chinese scholars also shared real-world research data on DAA applications at this year's AASLD
.
In a global, multi-center, large-scale real-world study of DAA in Asian populations[6], despite the existence of a large number of patients with liver cirrhosis, liver cancer, previous treatment failure, GT3 or type 6, the overall cure rate of patients is still As high as 96.
7%
.
Two other studies have revealed [7,8] that for the GT3 and 6 patients with less real-world evidence, the SOF/VEL±RBV regimen has a high sustained virological response rate and good safety
.
In addition, for special hepatitis C patients undergoing hemodialysis [9], the 12-week SOF/VEL regimen also achieved good safety and efficacy
.
These real-world data from the clinical frontline reflect the outstanding achievements made by Chinese scholars in hepatitis C clearance
.
As we all know, the hepatitis C micro-elimination strategy is to provide targeted services for specific hepatitis C patients in order to reduce the incidence and mortality of hepatitis C more quickly and effectively
.
At present, there are the latest reports on the mode of hepatitis C micro-elimination at home and abroad [10-12]
.
At this annual meeting, a study by the team of Professor Luo Xinhua from Guizhou Provincial People's Hospital received much attention.
The study conducted an online survey of hepatitis C prevention and treatment knowledge for medical workers in 17 hospitals in Guizhou Province [10]
.
The research results suggest that we need to continue to expand the education of primary health care workers to increase their awareness of hepatitis C; at the same time, accelerate the implementation of medical insurance and other comprehensive strategies to improve the accessibility of treatment options, so as to successfully achieve the 2030 WHO The goal of eradicating the hepatitis virus
.
Dr.
Michael Mertens-a breakthrough in treatment, HDV cannot be ignored! The transmission of HDV mainly depends on the transmission of HBV.
Studies have shown that HDV infection will accelerate the progression of hepatitis and increase the risk of liver adverse events [13], and patients with HBV combined with HDV infection have higher comorbidities and complications than HBV.
Single infection [14]
.
Therefore, we should increase the intensity of screening HDV improve the diagnosis and treatment of hepatitis
.
The current AASLD conference announced the Phase III clinical trial (MYR301) of Blevirtide [15].
The results showed that after 48 weeks of Blevirtide treatment, the level of HDV RNA and the number of HDAg+ cells in the liver decreased significantly
.
In addition, the decline of the virus in the liver is also related to the decline of inflammatory gene expression, indicating that liver inflammation has improved
.
What other issues do you care about? Come and vote and let us know! From 19:00-20:30 on November 30th, listen to the wonderful sharing and lead clinical ingenuity to see or leave! References[1]World Health Organization.
Global health sector strategy on viral hepatitis 2016-2021.
Geneva,Switzerland:World Health Organization.
Available via https:// en/Accessed 2020-07-28.
[2]https://cdafound.
org/dashboard/polaris/dashboard.
htmls[3]Miao Z,et al.
Estimating the Global Prevalence,Disease Progression,and Clinical Outcome of Hepatitis Delta Virus Infection.
J Infect Dis.
2020 Apr 27;221(10):1677-1687.
[4]Blach S,et al.
Global Status Update On the HCV Prevalence and Cascade of Care Entering 2020.
AASLD 2021.
Oral 100.
[ 5] Chen Yuxin, Wu Chao.
The management process of in-hospital screening for viral hepatitis C in China (for trial implementation).
Chinese Journal of Hepatology, 2020,28(10):820-823.
[6]Ji P,et al.
Real-World Effectiveness and Safety of Interferon-Free DAAS for 14,676 Hepatitis C(CHC)Patients with Genotypes 1,2,3,4 And 6: A Multinational Study.
AASLD 2021. .
If you are not a medical and health professional, please do not participate or spread it
.
-End-This article is only used to provide scientific information to medical professionals and does not represent the platform's position
.
